Is Co-Diagnostics' Stock in a Bubble?
Beyond the masks and protective gear used to prevent a disease's spread, vaccines to prevent those who are exposed from becoming ill, and therapies to treat those who do become sick, one key component of combating an epidemic is antibody testing.
Such tests are critically important because they reveal whether an individual has been infected with a specific disease in the past and has subsequently developed antibodies to prevent reinfection.
With countries around the world gradually allowing their economies to reopen up after weeks and months of lockdowns initiated to stem the spread of COVID-19, antibody tests will be in high demand as health officials race to figure out where the coronavirus has been, and to gauge whether a sufficient enough level of herd immunity has been achieved in various populations to protect seniors and the immunocompromised from the risk of infection. One company that claims to have developed an effective antibody test (called Logix) is Co-Diagnostics (NASDAQ: CODX).
Source Fool.com
